Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | NTRK1 fusion |
| Therapy | Larotrectinib |
| Indication/Tumor Type | high grade glioma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| NTRK1 fusion | high grade glioma | sensitive | Larotrectinib | Case Reports/Case Series | Actionable | In a clinical study, Vitrakvi (larotrectinib) treatment resulted in an overall response rate of 100% (8/8, 4 complete responses, 3 partial responses, 1 minor response) in patients with pediatric high-grade glioma harboring NTRK fusions (PMID: 39625867). | 39625867 |
| NTRK1 fusion | high grade glioma | sensitive | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines as adjuvant therapy for pediatric patients with diffuse high-grade gliomas harboring NTRK fusions, or as a preferred regimen for patients with recurrent or progressive disease (NCCN.org). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| NCCN.org | Full reference... | |
| (39625867) | Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions. | Full reference... |